Several procedural deadlines for the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting on peptides fall within the next few weeks. The committee is scheduled to consider whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon, in their free-base and acetate forms — should be eligible for compounding under…
The FDA’s public comment window on whether to keep three popular GLP-1 medicines off the 503B bulk drug substances list closes June 29, 2026. In an April 30, 2026 proposal, the FDA said it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances, given that FDA-approved versions…
mcg vs mg in peptide lab math: 1 mg equals 1000 mcg, how to convert, and how concentration (mg/mL) ties the units together with a worked example.
What research and the FDA label report about melanocortin side effects for PT-141 (Vyleesi) and Melanotan II, from nausea and flushing to mole changes.
What syringe gauge, needle length and the U-100 scale actually mean — plus dead space and why units measure volume, not dose. A clear research-handling guide.
A clear, sourced look at GLP-1 side effects for semaglutide and tirzepatide — the common GI effects, why they happen, and how tolerability is managed.
The FDA’s Pharmacy Compounding Advisory Committee will review BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon for the 503A compounding bulks list.
The FDA proposed not adding semaglutide, tirzepatide, and liraglutide to the 503B bulk substances list. A public comment period is open, closing on or around June 29, 2026.
BPC-157 came off the 503A Category 2 safety-risk list in April 2026 but is not yet on an approved bulks list, leaving its compounding status unresolved ahead of the July PCAC review.
Third-party analyses report a substantial share of online research peptides miss stated purity, and note that endotoxin can matter even at ~99% purity — reinforcing why COAs are worth reading.
